Early Heart Screening and Iron Treatment in Sickle Cell Disease
Tests early heart screening and iron-lowering treatment in adults with sickle cell disease.
Plain-language title generated from the registry record
Registry title: Early Screening and Treatment of Heart Complication in Sickle Cell Disease
Key facts
- Where
- Fairfax and Falls Church, United StatesSee the 2 sites
- Phase
- Phase 2
Where in United States
- Inova Schar CancerFairfax, United StatesTaking people
- Inova Health Care ServiceFalls Church, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Inova Health Care Services
- Trial code
- NCT07023666
- Record updated
- 9 September 2026
- Original description
This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.Read full original descriptionShow less
Early Detection and Management of Cardiac Iron Overload in Sickle Cell Disease Using Multimodal Imaging for Improved Clinical Outcomes
This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.
Inclusion: At least 18 years of age; Diagnosis of sickle cell disease (any genotype); Serum ferritin levels ≥ 400 ng/mL (up to 80 patients), or less than 400 ng/mL in those who have cardiac symptoms including shortness of breath and lower extremity edema (up to 20 patients); Willingness to undergo regular imaging (echocardiograms, ECG, cardiac MRI); ECOG performance status of 0-1; Able to read, understand and provide written informed consent; Deemed appropriate for participation by the treating physician.
Exclusion: Known heart failure; Unstable angina; Active infection or severe comorbid conditions that in the view of the investigator would limit participation; History of hypersensitivity or contraindication to chelation therapy; Severe renal or hepatic impairment; Unable to schedule and required follow-up visits; Medical comorbidities including:; Uncontrolled dysrhythmias; Acute pulmonary embolism; Pregnancy of breastfeeding.